Terumo Pharmaceutical Solutions Expands CDMO Services
The company is expanding its contract development and manufacturing services for parenteral drugs to global customers.
Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation, announced on Oct. 31, 2022 that it is expanding its contract development and manufacturing services for parenteral drugs to customers outside of Japan. The contract and development manufacturing organization (CDMO) offers end-to-end services with pre-filled syringe (PFS) design, molding, drug preparation, filling, assembly, and final packaging for biotech drugs and small molecules.
The expanded services would include early development stage to large-scale commercial production for global pharmaceutical customers, including assembly of PFS with devices such as autoinjectors and needle safety devices. The company would also offer customers global regulatory submissions support.
“I am excited for what the future holds for Terumo as we are in a unique position being able to offer an integrated solution of primary container, fill and finish capability, and device assembly, in addition to our traditional offering of injection, primary container, and infusion therapy devices,” said Marco Chiadò Piat, president of Terumo Pharmaceutical Solutions, in a press release.
Terumo will be showcasing the new global CDMO service at CPHI Frankfurt from Nov. 1–3, 2022.
Source: Terumo
